• 1. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
• 2. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 3. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 4. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 5. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527

Research Brief on 1-(6-chloro-2-methylsulfanylpyrimidin-4-yl)piperidin-4-ol (CAS: 1261231-33-7): Recent Advances and Applications

1-(6-chloro-2-methylsulfanylpyrimidin-4-yl)piperidin-4-ol (CAS: 1261231-33-7) is a chemical compound of significant interest in the field of medicinal chemistry and drug discovery. Recent studies have highlighted its potential as a key intermediate or active moiety in the development of novel therapeutic agents. This research brief synthesizes the latest findings related to this compound, focusing on its synthesis, biological activity, and potential applications in drug development.

Recent literature indicates that 1-(6-chloro-2-methylsulfanylpyrimidin-4-yl)piperidin-4-ol has been explored as a building block for kinase inhibitors, particularly targeting diseases such as cancer and inflammatory disorders. The compound's unique pyrimidine and piperidine scaffold offers versatile opportunities for structural modifications, enabling the optimization of pharmacokinetic and pharmacodynamic properties. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy in modulating specific kinase pathways, suggesting promise for targeted therapies.

In addition to its role in kinase inhibition, this compound has been investigated for its potential in central nervous system (CNS) drug development. Researchers have reported its ability to cross the blood-brain barrier, making it a candidate for treating neurological conditions. Preliminary in vitro and in vivo studies have shown encouraging results in models of neurodegenerative diseases, though further validation is required to confirm its therapeutic potential.

The synthetic routes for 1-(6-chloro-2-methylsulfanylpyrimidin-4-yl)piperidin-4-ol have also been refined in recent years. Advances in green chemistry and catalytic methods have improved yield and purity, reducing the environmental impact of its production. A 2022 patent application highlighted a novel one-pot synthesis method, which significantly streamlined the manufacturing process and reduced costs.

Despite these advancements, challenges remain in the clinical translation of derivatives based on this compound. Issues such as metabolic stability, selectivity, and toxicity profiles need to be addressed through further structure-activity relationship (SAR) studies. Collaborative efforts between academia and industry are essential to accelerate the development of viable drug candidates derived from this scaffold.

In conclusion, 1-(6-chloro-2-methylsulfanylpyrimidin-4-yl)piperidin-4-ol (CAS: 1261231-33-7) represents a promising chemical entity with diverse applications in drug discovery. Continued research into its biological mechanisms and synthetic optimization will be critical for unlocking its full therapeutic potential. This brief underscores the importance of interdisciplinary collaboration to advance this compound from bench to bedside.

• 1261229-47-3(1-(6-chloro-2-methylsulfanylpyrimidin-4-yl)piperidin-3-ol)
• 1420957-53-4((1-(6-Chloro-2-(methylthio)pyrimidin-4-yl)pyrrolidin-2-yl)methanol)
• 1261233-29-7((S)-1-(6-Chloro-2-(methylthio)pyrimidin-4-yl)pyrrolidin-3-ol)
• 1261232-57-8((1-(6-Chloro-2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)methanol)
• 55199-60-5(6-chloro-N-cyclohexyl-2-(methylthio)pyrimidin-4-amine)
• 1261234-17-6((R)-1-(6-Chloro-2-(methylthio)pyrimidin-4-yl)pyrrolidin-3-ol)
• 951884-56-3(4-Chloro-6-(3-Methoxypropylamino)-2-methylthiopyrimidine)
• 339017-59-3(4-Chloro-2-(methylthio)-6-(pyrrolidin-1-yl)pyrimidine)
• 261765-66-6(4-Pyrimidinamine,6-chloro-N-(cyclopropylmethyl)-2-(methylthio)-N-propyl-)
• 1353967-11-9(1-(6-Chloro-2-(methylthio)pyrimidin-4-yl)-1,4-diazepane hydrochloride)